ProMetic, NantPharma form NantPro for plasma-derived product development

PBR Staff Writer Published 03 August 2012


ProMetic Life Sciences and NantPharma have together formed an affiliate company, NantPro BioSciences, to develop and commercialize a plasma-derived biopharmaceutical product for the US market.



The new US based company has entered into development, licensing and manufacturing agreements with ProMetic.

Under the agreements, ProMetic has granted NantPro rights to its Plasma Protein Purification system and Prion Reduction technologies.

NantPharma said it has made an initial contribution of $2.5m to NantPro, which in turn paid all of these funds to ProMetic under various agreements for NantPro to access the technology rights from ProMetic.

NantPro has engaged ProMetic for the development and manufacturing services including the production in its Laval facility of cGMP bulk active batches to enable the IND filing and provide product required for bioequivalence clinical trials.

Upon FDA approval, ProMetic will manufacture and supply the commercial requirements of the cGMP bulk active with NantPharma completing the final sterile manufacturing steps, expected to occur at its Terre Haute, Indiana facility.

NantPharma chairman Patrick Soon-Shiong said plasma-derived products are needed for the treatment of auto-immune and other diseases.

"Safety and reliability are paramount in the manufacture of these products," Soon-Shiong added.

"The combination of ProMetic's state-of-the-art and proven technologies with NantPharma's expertise and resources, will enable us to produce the finest quality plasma-derived therapeutics for this vital market."

http://drugdiscovery.pharmaceutical-business-review.com/news/prometic-nantpharma-form-nantpro-for-plasma-derived-product-development-020812

+ insiders keep buying... Blackstone investment is involved... and Dr Soon-Shiong, a billionnaire, as well ( picked up 9% of PLI...), this guy is a very well known expert in the field, do your dd. That bidou troll: spammer or on bids. There's an Edison report on this Blog as well if interested.

http://canadianinsider.com/node/7?ticker=pli


As of 11:59pm ET September 25th, 2012
Filing
Date Transaction
Date Insider Name Ownership
Type Securities Nature of transaction # or value acquired or disposed of Price


Sep 19/12 Sep 19/12 Dumais, Frédéric Indirect Ownership Common Shares 10 - Acquisition in the public market 25,000
.130
Aug 15/12 Aug 15/12 Anthony, G.F. Kym Indirect Ownership Common Shares 10 - Acquisition in the public market 100,000
.145
Jul 19/12 Jul 18/12 Wygodny, Benjamin Indirect Ownership Common Shares 11 - Acquisition carried out privately 249,315
.120
Jul 19/12 Jul 18/12 Wygodny, Benjamin Indirect Ownership Common Shares 11 - Acquisition carried out privately 122,431
.120
Filing
Date Transaction
Date Insider Name Ownership
Type Securities Nature of transaction # or value acquired or disposed of Unit
Price
May 22/12 May 22/12 Pritchard, Bruce Indirect Ownership Common Shares 10 - Acquisition in the public market 144,000
.125
May 22/12 May 22/12 Pritchard, Bruce Indirect Ownership Common Shares 10 - Acquisition in the public market 56,000
.130
May 10/12 May 9/12 Liguori, Diane Lawrence Direct Ownership Options 00 - Opening Balance-Initial SEDI Report
Apr 27/12 Apr 26/12 Wygodny, Benjamin Indirect Ownership Common Shares 11 - Acquisition carried out privately 1,251,141
.135
Apr 27/12 Apr 26/12 Wygodny, Benjamin Indirect Ownership Common Shares 11 - Acquisition carried out privately 518,721
.135
Apr 19/12 Apr 17/12 Wygodny, Benjamin Direct Ownership Warrants 11 - Acquisition carried out privately 454,545
.180
Apr 19/12 Apr 17/12 Wygodny, Benjamin Direct Ownership Common Shares 11 - Acquisition carried out privately 1,136,363
.110
Mar 30/12 Mar 30/12 Dumais, Frédéric Indirect Ownership Common Shares 10 - Acquisition in the public market 50,000
.110